IMUGENE LIMITED — AGM Information 2024

Nov 13, 2024

==> picture [306 x 53] intentionally omitted <==

Leading Innovation in Cancer Treatment

AGM, November 2024

1

Disclaimer

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Imugene Limited (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation and particular needs of any particular investor.

Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk.

Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation.

==> picture [4 x 12] intentionally omitted <==

==> picture [4 x 11] intentionally omitted <==

==> picture [56 x 6] intentionally omitted <==

Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or

consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed.

Any opinions expressed reflect the Company’s position at the date of this presentation and are subject to change

International offer restrictions - This document does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction in which it would be unlawful. In particular, the New Shares have not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements of the US Securities Act and applicable US state securities laws. The distribution of this presentation in jurisdictions outside Australia may be restricted by law and any such restrictions should be observed.

2

==> picture [138 x 24] intentionally omitted <==

Imugene is a clinical stage cancer company developing three drug products in CAR T cell therapy and oncolytic viruses.

3

Seasoned and Highly Engaged Board Of Directors

==> picture [138 x 24] intentionally omitted <==

Diverse expertise, market sector leadership and catalysts for value creation

==> picture [106 x 128] intentionally omitted <==

Paul Hopper

Executive Chairman and Founder

==> picture [104 x 49] intentionally omitted <==

==> picture [114 x 37] intentionally omitted <==

==> picture [105 x 129] intentionally omitted <==

Dr. Jakob Dupont, MD

Non-Executive Director

==> picture [87 x 50] intentionally omitted <==

==> picture [88 x 29] intentionally omitted <==

==> picture [95 x 25] intentionally omitted <==

==> picture [96 x 22] intentionally omitted <==

==> picture [109 x 130] intentionally omitted <==

==> picture [106 x 129] intentionally omitted <==

Leslie Chong

Kim Drapkin

CEO & Managing Non-Executive Director Director and Chair of the Audit & Risk Committee

==> picture [126 x 26] intentionally omitted <==

==> picture [86 x 24] intentionally omitted <==

==> picture [92 x 26] intentionally omitted <==

==> picture [84 x 34] intentionally omitted <==

==> picture [60 x 32] intentionally omitted <==

==> picture [127 x 29] intentionally omitted <==

==> picture [46 x 41] intentionally omitted <==

==> picture [106 x 128] intentionally omitted <==

Dr. Lesley Russell

Non-Executive Director

==> picture [72 x 19] intentionally omitted <==

==> picture [97 x 24] intentionally omitted <==

==> picture [63 x 24] intentionally omitted <==

==> picture [74 x 26] intentionally omitted <==

==> picture [93 x 28] intentionally omitted <==

==> picture [105 x 128] intentionally omitted <==

Dr. Jens Eckstein

Non- Executive Director and Chair of the Remuneration & Nomination Committee

==> picture [53 x 47] intentionally omitted <==

==> picture [86 x 26] intentionally omitted <==

==> picture [86 x 29] intentionally omitted <==

4

Experienced Leadership Team has brought > 17 FDA Approved Drugs to Market

==> picture [108 x 129] intentionally omitted <==

==> picture [106 x 128] intentionally omitted <==

==> picture [106 x 128] intentionally omitted <==

==> picture [106 x 128] intentionally omitted <==

==> picture [105 x 129] intentionally omitted <==

Leslie Chong

Dr. Paul Woodard, MD

Dr. Bradley Glover, PhD MBA

Ursula McCurry

Dr. John Byon, MD, PhD Senior VP of Clinical Development

Chief Executive Officer & Managing Director

Chief Medical Officer

Chief Clinical Chief Operating Officer Operations Officer

==> picture [98 x 30] intentionally omitted <==

==> picture [89 x 28] intentionally omitted <==

==> picture [51 x 28] intentionally omitted <==

==> picture [86 x 25] intentionally omitted <==

==> picture [82 x 16] intentionally omitted <==

==> picture [82 x 22] intentionally omitted <==

==> picture [92 x 26] intentionally omitted <==

==> picture [51 x 37] intentionally omitted <==

==> picture [83 x 24] intentionally omitted <==

==> picture [86 x 25] intentionally omitted <==

==> picture [87 x 25] intentionally omitted <==

==> picture [55 x 30] intentionally omitted <==

==> picture [61 x 33] intentionally omitted <==

==> picture [92 x 26] intentionally omitted <==

==> picture [65 x 29] intentionally omitted <==

==> picture [71 x 19] intentionally omitted <==

==> picture [95 x 22] intentionally omitted <==

==> picture [98 x 40] intentionally omitted <==

==> picture [46 x 41] intentionally omitted <==

==> picture [93 x 26] intentionally omitted <==

==> picture [87 x 24] intentionally omitted <==

==> picture [70 x 19] intentionally omitted <==

==> picture [138 x 24] intentionally omitted <==

==> picture [105 x 128] intentionally omitted <==

Dr. Monil Shah

Head of Business Development (consultant)

==> picture [80 x 30] intentionally omitted <==

==> picture [99 x 17] intentionally omitted <==

==> picture [70 x 18] intentionally omitted <==

==> picture [97 x 17] intentionally omitted <==

==> picture [73 x 42] intentionally omitted <==

5

Investment Highlights

==> picture [138 x 24] intentionally omitted <==

Market Capitalisation A$342M Cash Position As of 13 November 2024 PLATFORM LONGTECHNOLOGIES 4 LIFE PATENT PORTFOLIO azer-cel Ph1b DLBCL (FDA IND) CLINICAL VAXINIA: Ph1 Solid Tumours (FDA IND) 4 STUDIES onCARlytics: Ph1 Solid Tumours (FDA IND) > 200 cancer patients dosed PD1-Vaxx: Ph2 neoPOLEM

Cash Position As of 30 September 2024

A$54.3M (Pro-forma) DISEASE AREAS

==> picture [96 x 253] intentionally omitted <==

Blood cancers Breast (TNBC) Lung (NSCLC) Gastric Gastroesophageal Colorectal (CRC) Melanoma Head and Neck Cholangiocarcinoma Pancreatic Bladder

6

Three Novel Cancer Technologies In Clinical Trials

==> picture [138 x 24] intentionally omitted <==

==> picture [230 x 26] intentionally omitted <==

==> picture [211 x 27] intentionally omitted <==

onCARlytics CD19 targeting virus OASIS Trial

CF33 Oncolytic Virus azer-cel CD19 CAR T VAXINIA MAST Trial Phase 1b Phase 1

Phase 1b Phase 1 Phase 1 Novel virus which acts as a CD19 target in Off-the-shelf drug, aka “Allo” geneic Novel cancer killing virus solid cancers Targeting a range of late-stage solid Targeting blood cancers cancers Makes solid cancers visible to CD19 drugs Positive Phase 1 data in 84 patients Phase 1 trial with >40 patients enrolled Currently in Phase 1 in combination with Blinatumomab (Approved CD19 drug in blood cancers) in solid cancers Encouraging results in bile tract cancer Currently in Phase 1b FDA IND FDA IND FDA IND

7

What is Autologous CAR T Therapy?

==> picture [222 x 25] intentionally omitted <==

A cancer treatment in which a patient’s T-cells are reprogramed in a laboratory so that they become like a guided missile to attack certain proteins (ie CD19) on the cancer cells − CAR T stands for chimeric antigen receptor T-cell. Currently many CD19 targeted auto CAR Ts are approved and only in blood cancers.

==> picture [823 x 209] intentionally omitted <==

----- Start of picture text -----

blood
Patient’s T-cells
cancer cell
reprogrammed CAR T CD19
into CD 19
T-cells taken from targeted CAR T
patient’s blood
Two types of CAR Ts
CD19
----- End of picture text -----

==> picture [516 x 133] intentionally omitted <==

----- Start of picture text -----

Personalised aka Off the shelf aka allogeneic /allo
autologous /auto. Made from healthy donor T-cells
Made from the patient’s own T- that provide CAR T drug that
cells and only works for them works for many patients
----- End of picture text -----

8

==> picture [222 x 25] intentionally omitted <==

What is Imugene’s azer-cel Allogeneic CAR T?

Azer-cel is currently enrolling patients with a rare form of blood cancer known as diffuse large B cell lymphoma (DLBCL) for patients who have failed approved treatments

Approximately 30,000 cases (US) per year of DLBCL blood cancer[1]

Azer-cel is an

‘off-the-shelf’ CAR T drug,

aka allogeneic, which is made from healthy donor T-cells that provide CAR T drug that works for many patients

CAR T drugs have revolutionised treatments for blood cancer

The large Phase 1 trial demonstrated safety and encouraging signs of efficacy

Currently in a Phase 1b trial in leading US and Australian centres

A Phase 1 clinical trial in 84 patients was completed across twelve leading cancer centres in the US

The technology was acquired in September 2023

==> picture [172 x 413] intentionally omitted <==

----- Start of picture text -----

Hold space for Paul
----- End of picture text -----

9

1https://ascopost.com/news/november-2023/novel-strategy-may-improve-outcomes-in-patients-with-treatment-resistant-dlbcl/

67% Complete Response Rates Observed in Phase 1b Cohort B

==> picture [222 x 25] intentionally omitted <==

Evaluable patients: Evaluable Evaluable Cohort A+B patients: patients: (N=9) Cohort A (N=6) Cohort B (N=3) Overall Response 4 (44%) 2 (33%) 2 (67%) Rate % Complete 3 (33%) 1 (17%) 2 (67%) Response % Best Durability >120 days on (Time of <60 days going response)

10

Cohort B Results

• The first 2 patients treated achieved a complete response (CR), 1 patient had stable disease (SD), 1 patient yet to be evaluated

• Responses were seen in patients who failed multiple prior treatments, including autologous CAR T therapies

1Lymphodepletion(LD)/chemotherapy: Aug Cy: Flu 30mg/m2 x 3d, Cy 750mg/m2 x 3d

• Phase 1b trial continues to enrol patients into Cohort B across leading cancer centres in the U.S. and Australia including, Columbia University, University of Minnesota, Emory and Moffitt Cancer Centres and Royal Price Alfred Hospital

10

Representative PET Scans Of Complete Responses

Subject Treatment Summary

• 47 yo female, first diagnosed with High-grade B- cell lymphoma (HGBCL), stage IV in Jul 2022. Treated at Emory University.

• Prior to azer-cel, patient failed 4 prior lines of therapy; R-CHOP; R-DHAP, Yescarta , and Prednisone

• Pathologist report revealed neoplastic cells were positive (90%) for CD19 by flow

• Azer-cel treatment regimen

• Augmented Cy conditioning regimen (750 mg/m2/d (3d) Cyclophosphamide i.v. + 30 mg/m2/d (3d) fludarabine iv) + low dose SC IL-2

• DL4b (500 x 106 CAR T cells )

Tumour-free

Tumour

==> picture [134 x 223] intentionally omitted <==

==> picture [106 x 226] intentionally omitted <==

==> picture [105 x 223] intentionally omitted <==

Baseline

Day 28

Day 60

==> picture [104 x 226] intentionally omitted <==

==> picture [52 x 14] intentionally omitted <==

----- Start of picture text -----

Day 90
----- End of picture text -----

• Notable Safety Events–No CRS/ICANS

• Response – CR @ D28, D60 & D90

11

==> picture [208 x 27] intentionally omitted <==

CF33 VAXINIA Can Infect and Kill Cancer Cells

==> picture [76 x 112] intentionally omitted <==

==> picture [58 x 57] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

==> picture [67 x 63] intentionally omitted <==

==> picture [55 x 32] intentionally omitted <==

==> picture [55 x 32] intentionally omitted <==

==> picture [55 x 32] intentionally omitted <==

Cell explodes, releasing thousands of brand new virus particles

Virus duplicates itself

Virus enters tumour cell

Engineering enhancements

• Infect and kill only cancer cells

• Carry payloads to increase killing

Multiple ways to kill cancer cells

• Direct killing

• Activation of immune cells to kill cancer cells

• Priming the tumour environment to enhance immune response[1]

Precedent for approval

• Tvec approved in the United States for skin cancer (2015)

• Oncorine approved in China for head and neck cancer (2005)

• Delytact approved in Japan for brain cancer (2021)

TME: tumour microenvironment 1. Ribas et al., Cell 170:1109, 2017

12

Phase 1 MAST Trial − Encouraging Early Signals

==> picture [36 x 34] intentionally omitted <==

Patients[1]

• 40 patients have been dosed and evaluated (at least their first scan at day 42)

==> picture [208 x 27] intentionally omitted <==

==> picture [121 x 50] intentionally omitted <==

==> picture [123 x 35] intentionally omitted <==

==> picture [36 x 36] intentionally omitted <==

==> picture [36 x 36] intentionally omitted <==

==> picture [33 x 32] intentionally omitted <==

Disease Control So Far

• Nearly half of the evaluable patients (48%) have remained on treatment for >3 months

• 3 patients have remained on treatment for >200 days

Responses

• Patient with bile tract cancer who had a complete response (CR); ongoing remission for >2 years

• 2 patients with melanoma had partial responses (PRs); 17 patients achieved stable disease (SD)

Bile Tract Trial

• Bile tract cancer expansion trial opened based on positive response

• First cohort cleared, establishing safety

Fast Track and Orphan Drug Designation

• US FDA Fast Track Designation for bile tract cancer, which allows for faster review

• US FDA Orphan Drug Designation for bile tract cancer, which allows for further efficiencies

==> picture [99 x 61] intentionally omitted <==

==> picture [128 x 28] intentionally omitted <==

==> picture [141 x 35] intentionally omitted <==

==> picture [140 x 33] intentionally omitted <==

==> picture [164 x 49] intentionally omitted <==

FAST TRACK Orphan Drug Designation Designation

1Preliminary study update as of June 2024; data and number of evaluable patients subject to change with full statistical analysis

13

What is Imugene’s onCARlytics CD19 virus?

Imugene’s novel onCARlytics CD19 virus, makes a solid cancer “resemble” a CD19 blood cancer cell, and lures FDA approved anti-CD19 CAR T drugs, to attack them

Solid cancers do not have the CD19 molecule on their cell surface

IMU’s CD19 virus causes solid cancers to display (create a target) the CD19 molecule on their cell surface

This makes them a killing target for anti-CD19 CAR T blood cancer drugs

Insert CD19 CD19 virus CD19 displayed on virus infects cell cell surface

==> picture [232 x 203] intentionally omitted <==

----- Start of picture text -----

Cancer cell appears as a
CD19 target
CD19
----- End of picture text -----

==> picture [134 x 39] intentionally omitted <==

----- Start of picture text -----

CD19 drug “sees” solid
cancer cell and
attacks & kills
----- End of picture text -----

==> picture [119 x 140] intentionally omitted <==

Solid Cancer Cell

Solid Cancer Cell

Solid Cancer Cell

==> picture [106 x 11] intentionally omitted <==

----- Start of picture text -----

Solid Cancer Cell
----- End of picture text -----

E.g. Breast, Melanoma, Lung, Gastric etc.

14

2024 Highlights

azer-cel : Three Complete Responses in azer-cel Phase 1B DLBCL trial

azer-cel : First Australian site open for Phase 1b Clinical Trial

VAXINIA : Positive early trial update; 1 CR (in remission for over 2 years), 2 PRs, All treatments determined to be safe and tolerable

VAXINIA : Orphan Drug Designation for treatment of Bile Tract Cancer, giving 7 years of market exclusivity

VAXINIA : Bile Tract cancer trial open and first cohort cleared

VAXINIA : Oncolytic Virotherapy CF33 patent granted in China and CF33 patent extension to 2040 in US

onCARlytics : OASIS IV and IT Monotherapy cohort cleared

onCARlytics : OASIS Combination arm open, FPI in IV and IT Combo

==> picture [138 x 24] intentionally omitted <==

==> picture [267 x 270] intentionally omitted <==

Key

DLBCL : Diffuse Large B-Cell Lymphoma (Blood Cancer)

CR: Complete Response PR: Partial Response FPI: First Patient In Combo : Combination Therapy Mono : Monotherapy

IT : Intratumoural, IV : Intravenous

15

Expected Upcoming Key Catalysts H2 2024/2025

==> picture [138 x 24] intentionally omitted <==

• azer-cel : DLBCL Phase 1b interim data update

• azer-cel : Target regulatory meeting with FDA

• azer-cel : FPI in Phase 2 study

• azer-cel : Expansion into additional blood cancers (Phase 1b Expansion Cohort)

• onCARlytics : IT and/or IV Combo status

• onCARlytics : Data update and trial expansion

• onCARlytics: Optimal Biological Dose (OBD) Established

• onCARlytics + azer-cel FDA IND and FPI in solid tumours

• onCARlytics: Phase 2 Start-up

• VAXINIA : Second indication trial open

==> picture [268 x 288] intentionally omitted <==

• VAXINIA: Optimal Biological Dose Established for IT and/or IV monotherapy

Key

• VAXINIA: Phase 2 Study Open

• VAXINIA : Phase 2 FPI

• VAXINIA : IP & IA Phase 1 FPIs

FPI: First Patient In

Combo : Combination Therapy Mono : Monotherapy

DLBCL : Diffuse Large B-Cell Lymphoma (Blood Cancer)

IT : Intratumoural, IV : Intravenous

16

Imugene Commercialisation Strategy Multiple Value Realisation Pathways

They often manage more COMPANY ACQUISITION money than hedge funds or mutual funds

Due to the network effect, each financial advisor represents hundreds of potential shareholders DEVELOP /

PARTNER WITH BIG These investors have the They make decisions quickly LICENSE ability to purchase stock PHARMA without the bureaucracy of TECHNOLOGIES immediately traditional investment firms SEPARATELY

• The global model for biotech commercialisation is to out-license the technology to Big Pharma in Phase 1b/2 trials

• Conducting Phase 3 trials, obtaining FDA approval for the product not within the remit of biotech

• Out-licensing is highly dependent upon demonstrating safety in Phase 1 and convincing signals of efficacy in Phase 1b/2

• Licensing deals are generally structured with an up-front cash payment, payments upon reaching certain development milestones such as entering Phase 3 trials, payment on FDA approval of the drug, and royalties on net sales when the drug is on the market

17

ASX : IMU

shareholderenquiries@imugene.com imugene.com

==> picture [259 x 52] intentionally omitted <==

18